Four products are in development for hematology and oncology indications:
- SANGUINATE®, the Company’s lead product, is in clinical development with a focus on treating vaso-occlusive crisis of sickle cell disease and other disorders caused by ischemia, hypoxia and/or hemolysis.
- ANF-Rho™ is the result of combining state-of-the-art protein engineering technology with advanced PEGylation techniques to create a novel molecule with a unique mechanism of action. It is in clinical development for the treatment of febrile neutropenia.
- EPEG® is a long-acting third generation PEGylated EPO biologic in clinical development for the treatment of anemia, a comorbidity common with both chronic kidney disease and cancer chemotherapy. Phase I trials are completed. Prolong retains development and commercialization rights in the US, Europe, and China. Zydus-Cadila has development and commercialization rights in the rest of the world.
- PP-403 is a novel cytokine with broad applications in cancer.